These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

77 related articles for article (PubMed ID: 21115895)

  • 41. Role of metallothionein in cisplatin sensitivity of germ-cell tumours.
    Meijer C; Timmer A; De Vries EG; Groten JP; Knol A; Zwart N; Dam WA; Sleijfer DT; Mulder NH
    Int J Cancer; 2000 Mar; 85(6):777-81. PubMed ID: 10709094
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Radiation-induced apoptosis in F9 teratocarcinoma cells.
    Langley RE; Palayoor ST; Coleman CN; Bump EA
    Int J Radiat Biol; 1994 May; 65(5):605-10. PubMed ID: 7910198
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Platinum derivatives: a multidisciplinary approach.
    Gheorghe-Cetean S; Cainap C; Oprean L; Hangan A; Virag P; Fischer-Fodor E; Gherman A; Cainap S; Constantin AM; Laszlo I; Vlad C; Oprean R
    J BUON; 2017; 22(3):568-577. PubMed ID: 28730758
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Assessment of platinum sensitivity in human tumor cells.
    Zisowsky J; Becker A; Weykam S; Kassack M; Jaehde U
    Int J Clin Pharmacol Ther; 2003 Dec; 41(12):612-3. PubMed ID: 14692716
    [No Abstract]   [Full Text] [Related]  

  • 45. Comparable effectiveness and immunomodulatory actions of oxaliplatin and cisplatin in electrochemotherapy of murine melanoma.
    Ursic K; Kos S; Kamensek U; Cemazar M; Scancar J; Bucek S; Kranjc S; Staresinic B; Sersa G
    Bioelectrochemistry; 2018 Feb; 119():161-171. PubMed ID: 29024870
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Overcoming tumor resistance to cisplatin through micelle-mediated combination chemotherapy.
    Zhou D; Cong Y; Qi Y; He S; Xiong H; Wu Y; Xie Z; Chen X; Jing X; Huang Y
    Biomater Sci; 2015 Jan; 3(1):182-91. PubMed ID: 26214201
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Overcoming cisplatin resistance in chemotherapy by biomineralization.
    Chen W; Xiao Y; Liu X; Chen Y; Zhang J; Xu X; Tang R
    Chem Commun (Camb); 2013 May; 49(43):4932-4. PubMed ID: 23604226
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Complementation analysis of testis tumor cells.
    Wang X; Hafezparast M; Masters JR
    Cancer Genet Cytogenet; 1997 Oct; 98(1):56-62. PubMed ID: 9309119
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Differential cisplatin responses in human carcinoma cell lines pre-exposed to fractionated X-irradiation.
    Dempke WC; Hosking LK; Shellard SA; Hill BT
    Biochem Soc Trans; 1991 Apr; 19(2):121S. PubMed ID: 1889526
    [No Abstract]   [Full Text] [Related]  

  • 50. The molecular basis of cisplatin sensitivity/resistance.
    Kelland LR
    Eur J Cancer; 1994; 30A(6):725-7. PubMed ID: 7917526
    [No Abstract]   [Full Text] [Related]  

  • 51. A mechanism of IL-34-induced resistance against cytotoxic anti-cancer therapies such as radiation by X-ray and chemotherapy by Oxaliplatin.
    Han N; Wada H; Kobayashi T; Otsuka R; Seino KI
    Oncoimmunology; 2023; 12(1):2238499. PubMed ID: 37533702
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Requirements for potentiation of radiation effect by a plantinum complex.
    Szumiel I
    Int J Radiat Biol Relat Stud Phys Chem Med; 1978 Jun; 33(6):605-8. PubMed ID: 308057
    [No Abstract]   [Full Text] [Related]  

  • 53. Testicular cancer: Genetic determinants of cisplatin resistance.
    Thoma C
    Nat Rev Urol; 2016 Nov; 13(11):629. PubMed ID: 27698397
    [No Abstract]   [Full Text] [Related]  

  • 54. NONO and RALY proteins are required for YB-1 oxaliplatin induced resistance in colon adenocarcinoma cell lines.
    Tsofack SP; Garand C; Sereduk C; Chow D; Aziz M; Guay D; Yin HH; Lebel M
    Mol Cancer; 2011 Nov; 10():145. PubMed ID: 22118625
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Sequential X-irradiation induced acquired resistance to oxaliplatin but increased sensitivity to cisplatin in two human teratoma cell lines in vitro.
    Eisenmann S; Voigt W; Müller T; Dempke W
    Anticancer Res; 2010 Nov; 30(11):4471-6. PubMed ID: 21115895
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Resistance mechanisms following cisplatin and oxaliplatin treatment of the human teratocarcinoma cell line 2102EP.
    Rennicke A; Voigt W; Mueller T; Fruehauf A; Schmoll HJ; Beyer C; Dempke W
    Anticancer Res; 2005; 25(2A):1147-55. PubMed ID: 15868958
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Failure of activation of caspase-9 induces a higher threshold for apoptosis and cisplatin resistance in testicular cancer.
    Mueller T; Voigt W; Simon H; Fruehauf A; Bulankin A; Grothey A; Schmoll HJ
    Cancer Res; 2003 Jan; 63(2):513-21. PubMed ID: 12543810
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Human melanoma cells selected for resistance to apoptosis by prolonged exposure to tumor necrosis factor-related apoptosis-inducing ligand are more vulnerable to necrotic cell death induced by cisplatin.
    Zhang XD; Wu JJ; Gillespie S; Borrow J; Hersey P
    Clin Cancer Res; 2006 Feb; 12(4):1355-64. PubMed ID: 16489094
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Combining radiation with oxaliplatin: a review of experimental results.
    Hermann RM; Rave-Fränk M; Pradier O
    Cancer Radiother; 2008 Jan; 12(1):61-7. PubMed ID: 18243751
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Unravelling mechanisms of cisplatin sensitivity and resistance in testicular cancer.
    Koster R; van Vugt MA; Timmer-Bosscha H; Gietema JA; de Jong S
    Expert Rev Mol Med; 2013 Sep; 15():e12. PubMed ID: 24074238
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.